Informes:
Tels.: (+ 52) 55 5135 0586 /
(+ 52) 55 5135 7034

contacto@vector-pharma.com

PROGRAMA

Lunes 5 de junio

10:00 hrs

Conferencia magistral

"Balancing healthcare costs at a time of innovation"

Alan Sheppard
Principal, Global Generics and Biosimilars Thought Leadership
Quintiles IMS

 

 
Alan has over 45 years extensive experience within the healthcare industry, including innovator R&D pharmaceuticals, OTC and generic companies and working with Government departments, law firms, venture capital companies and industry associations.

Heading up the global generics arm of QuintilesIMS Thought Leadership Alan is responsible for developing services and insights for the industry and its associations on generic medicines and biosimilars through a combination of consulting, information and market analyses.

Previous positions held include Executive Vice-President, Europe Generics, for Dr Reddy’s Laboratories Ltd; Vice-President of Global Corporate Strategy for PLIVA (now Teva); European Marketing Director for Medeva (now UCB); General Manager, Rhône-Poulenc Rorer UK (now Sanofi); General Manager, Institute Mérieux UK; and management roles with Servier Laboratories and SmithKline & French.

Alan is also an expert witness on patent litigation issues and their commercial impact, working with leading international law firms.

Other roles have included Chairman of the Technical Advisory Group for the Access to Medicines Foundation; guest lecturer at the University of Wales working in the medicines faculty specialising in pharmaceutical marketing; a long serving member of the Prescription Medicines Code of Practice Authority Appeals Board; a Fellow of the Chartered Institute of Management; Fellow of the International Doctors’ Association and Member of the Chartered Institute of Marketing.

 

REGRESAR AL PROGRAMA

 


Informes
Tels.: (+ 52) 55 5135 0586 y (+ 52) 55 5135 7034

contacto@vector-pharma.com

________________________________________________________________________________________________________________________________________________________________________

NTA